Skip To Main Content
Maria Cohut on Muck Rack

Maria Cohut

Verified
Brighton
As seen in: Medical News Today, Aol, Metro (UK), Healthline, Lonely Planet, Greatist, Times Higher Education, EIN News, Genetic Literacy Project, NewsBreak, Nigerian Tribune and
Feature editor at medicalnewstoday.com. Interested in the brain🧠, weird science, med history, our relationship with our bodies in and after life💀. She/her.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maria

Contact Maria, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Does fructose contribute to the spread of ovarian cancer? What we know Original

|
By Maria Cohut Verified
| Medical News Today Verified
Share on Pinterest Fructose may play a key role in the spread of ovarian cancer, a preclinical study suggests. Abraham Gonzalez Fernandez/ Getty Images Ovarian cancer, doctors explain, can be hard to treat as it may go undiagnosed for a long time. That also makes the cancer more likely to spread through the body.
Open in Who Shared View Duplicates (2) Issue with article?

Does fructose contribute to the spread of ovarian cancer? What we know

|
By Maria Cohut Verified
| healthgrades.com
Fructose may play a key role in the spread of ovarian cancer, a preclinical study suggests. Abraham Gonzalez Fernandez/ Getty Images Ovarian cancer, doctors explain, can be hard to treat as it may go undiagnosed for a long time. That also makes the cancer more likely to spread through the body.
Open in Who Shared Issue with article?

How does Lipfendra compare to statins? Expert answers 5 key questions

|
By Maria Cohut Verified
| Medical News Today Verified
Share on Pinterest A cardiologist explains everything you need to know about Lipfendra, the newly FDA-approved cholesterol-lowering pill. Guido Mieth/ Getty Images The Food and Drug Administration (FDA) approved Lipfendra (enlicitide), a new oral treatment for high cholesterol (hypercholesterolemia) and heterozygous familial hypercholesterolemia, on July 16, 2026.
Open in Who Shared Issue with article?
See all 2,151 licensed articles (2,153 Total)